The global oral solid dosage contract manufacturing market is expected to reach USD 21 billion in 2023 anticipated to grow at a CAGR of 5% during the forecast period 2023-2035.

Over time, the growing complexity of active pharmaceutical ingredients (APIs) has driven the creation of various innovative formulations, enabling targeted drug delivery. However, the demand for oral solid dosage (OSD) forms like tablets and capsules remains unmatched, constituting more than two-thirds of prescribed medications worldwide. These OSDs are favored for their cost-effectiveness, stability compared to larger molecules, and ease of patient administration, which greatly improves medication adherence. The increasing prominence of orally administered small molecules addresses adherence issues, leading to a crucial role in medication delivery. As the need for oral solid drugs rises, the development of modified solid formulations?from disintegrating tablets (ODTs) to combination products and extended-release forms?provides a significant opportunity for drug developers to stand out in this competitive and mature market. These formulations aim to enhance API solubility and increase bioavailability, meeting market demands and patient requirements. However, manufacturing specialized solid doses, especially those with highly potent APIs, involves a complex process spanning early formulation development to scaling up, demanding diverse expertise and a deep understanding of multiple disciplines. Consequently, drug developers increasingly rely on contract manufacturing organizations with specialized machinery and skilled teams. These contract manufacturers tackle technical complexities and operational challenges, such as intricate formulations, strict regulatory requirements, and handling multiple suppliers. The widespread preference for oral solid dosage forms, particularly among pediatric and geriatric populations, is expected to significantly drive the growth of the oral solid dosage contract manufacturing market in the foreseeable future, encompassing both conventional and modified formulations.

Report Coverage
? The report examines the oral solid dosage manufacturing market across various parameters such as the type of finished dosage form, type of packaging, scale of operation, company size, therapeutic area, and key geographical regions.
? An analysis of market growth factors (including drivers, restraints, opportunities, and challenges) is conducted within the report.
? It evaluates the potential advantages and challenges within the market landscape for stakeholders and offers insights into the competitive environment among leading market players.
? The report provides revenue forecasts for market segments concerning five major regions.
? Through comprehensive research, it presents an in-depth analysis of the oral solid dosage contract manufacturing market, encompassing:
? Explanation of oral solid dose form types and components, outlining the manufacturing process, and discussing emerging trends in outsourced manufacturing operations.
? Analysis of companies providing oral solid dosage manufacturing services based on establishment year, company size, ownership, offered services, manufactured dosage forms, packaging types, operational scales, and additional capabilities.
? Evaluation of manufacturers’ competitiveness based on supplier and service strengths, considering experience, offered services, dosage forms, packaging, operational scales, certifications, and facility locations.
? Examination of manufacturers’ capabilities across key regions, detailing service offerings, dosage forms, packaging, operational scales, and facility locations.
? Detailed profiles of prominent oral solid dosage contract manufacturers, covering company overview, financial data (if available), service portfolios, manufacturing capabilities, recent developments, and future outlook.
? Discussion on factors influencing drug developers’ decisions between in-house manufacturing and partnering with CMO or CDMO for oral solid dosage production.
? Analysis of expansions since 2018, their purpose, types, estimation of global installed capacity distribution among firms, operational scales, dosage forms, and regions.
? Estimation of annual clinical and commercial demand for oral solid doses, coupled with a detailed analysis of the total cost of ownership for manufacturing facilities over a 20-year period.
? Review of regulatory guidelines across countries, assessment of over 300 CMOs for operational approvals, certifications, and regulatory compliance, along with a comparative analysis of regulatory scenarios in key regions.
? Detailed case studies on taste masking and bioavailability enhancement service providers, including information on technologies, scale of operation, end users, techniques employed, regional capabilities, and market landscapes.

Key Market Companies
? Aenova, Alcami
? Almac
? Cambrex
? Catalent
? Hetero Drugs
? Ind-Swift
? Laboratories
? Lonza
? Rubicon Research